SG11201502032VA - Pyrrolotriazinone derivatives as pi3k inhibitors - Google Patents
Pyrrolotriazinone derivatives as pi3k inhibitorsInfo
- Publication number
- SG11201502032VA SG11201502032VA SG11201502032VA SG11201502032VA SG11201502032VA SG 11201502032V A SG11201502032V A SG 11201502032VA SG 11201502032V A SG11201502032V A SG 11201502032VA SG 11201502032V A SG11201502032V A SG 11201502032VA SG 11201502032V A SG11201502032V A SG 11201502032VA
- Authority
- SG
- Singapore
- Prior art keywords
- pi3k inhibitors
- pyrrolotriazinone derivatives
- pyrrolotriazinone
- derivatives
- pi3k
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382399 | 2012-10-16 | ||
| US201261718782P | 2012-10-26 | 2012-10-26 | |
| PCT/EP2013/071551 WO2014060432A1 (fr) | 2012-10-16 | 2013-10-15 | Dérivés de pyrrolotriazinone en tant qu'inhibiteurs des pi3k |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502032VA true SG11201502032VA (en) | 2015-05-28 |
Family
ID=47049114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502032VA SG11201502032VA (en) | 2012-10-16 | 2013-10-15 | Pyrrolotriazinone derivatives as pi3k inhibitors |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9388189B2 (fr) |
| EP (1) | EP2909207A1 (fr) |
| JP (1) | JP2015533181A (fr) |
| KR (1) | KR20150068953A (fr) |
| CN (1) | CN104854108A (fr) |
| AP (1) | AP2015008328A0 (fr) |
| AR (1) | AR093036A1 (fr) |
| AU (1) | AU2013333938A1 (fr) |
| BR (1) | BR112015007231A2 (fr) |
| CA (1) | CA2883426A1 (fr) |
| CL (1) | CL2015000956A1 (fr) |
| CR (1) | CR20150175A (fr) |
| DO (1) | DOP2015000077A (fr) |
| EA (1) | EA027277B1 (fr) |
| GE (1) | GEP201706623B (fr) |
| GT (1) | GT201500094A (fr) |
| HK (1) | HK1211027A1 (fr) |
| IL (1) | IL237475A0 (fr) |
| MD (1) | MD20150048A2 (fr) |
| MX (1) | MX2015004327A (fr) |
| NI (1) | NI201500054A (fr) |
| PE (1) | PE20150637A1 (fr) |
| PH (1) | PH12015500813B1 (fr) |
| SG (1) | SG11201502032VA (fr) |
| TN (1) | TN2015000112A1 (fr) |
| TW (1) | TW201429975A (fr) |
| UY (1) | UY35086A (fr) |
| WO (1) | WO2014060432A1 (fr) |
| ZA (1) | ZA201501220B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014015523A1 (fr) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Nouveaux composés hétéroaryliques et hétérocycliques et compositions et procédés s'y rapportant |
| US9682083B2 (en) * | 2013-05-14 | 2017-06-20 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| AU2014321419B2 (en) | 2013-09-22 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| WO2016001855A1 (fr) | 2014-07-04 | 2016-01-07 | Lupin Limited | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k |
| WO2016054491A1 (fr) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| WO2016202800A1 (fr) | 2015-06-16 | 2016-12-22 | Almirall, S.A. | Dérivés de pyrrolotriazinone en tant qu'inhibiteurs de pi3k |
| CN106467545B (zh) * | 2015-08-20 | 2018-10-16 | 北大方正集团有限公司 | 一种噻吩并嘧啶化合物 |
| WO2017076990A1 (fr) | 2015-11-05 | 2017-05-11 | Almirall, S.A. | Sels d'addition de n-[4-(4-{[(1s)-1-(5-méthyl-4-oxo-3-phényl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)éthyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide |
| CA3004530A1 (fr) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methodes et compositions comprenant une therapie genique suppressive de tumeur et le blocage du point de controle immunitaire pour le traitement du cancer |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| US10561660B2 (en) * | 2016-06-21 | 2020-02-18 | Nerviano Medical Sciences S.R.L. | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
| SG11201901197PA (en) | 2016-08-24 | 2019-03-28 | Arqule Inc | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| EP3768698A4 (fr) | 2018-03-19 | 2022-03-30 | MultiVir Inc. | Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer |
| WO2021113644A1 (fr) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer |
| WO2022000443A1 (fr) * | 2020-07-03 | 2022-01-06 | Nanjing Immunophage Biotech Co., Ltd. | Méthodes et compositions pour cibler des treg au moyen d'inhibiteurs de ccr8 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785363B1 (ko) * | 2000-04-25 | 2007-12-18 | 이코스 코포레이션 | 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제 |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| US6752411B2 (en) | 2002-06-24 | 2004-06-22 | Norco Industries, Inc. | Multi-stage torsion axle |
| TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| US7417055B2 (en) | 2003-04-25 | 2008-08-26 | Gilead Sciences, Inc. | Kinase inhibitory phosphonate analogs |
| WO2005016348A1 (fr) | 2003-08-14 | 2005-02-24 | Icos Corporation | Methodes d'inhibition de reponses immunes stimulees par un facteur endogene |
| WO2005113554A2 (fr) * | 2004-05-13 | 2005-12-01 | Icos Corporation | Méthode de préparation du 3-phényle-2-[9h-purine-6-ylamino)-méthyle]-3h-quinazoline-4-un et composés substitués et associés |
| DK200400182U4 (da) | 2004-06-23 | 2005-10-14 | Alfa Laval Tank Equipment As | Drivenhed især til brug i forbindelse med tankrenseudstyr |
| GB0417709D0 (en) | 2004-08-09 | 2004-09-08 | Glaxo Group Ltd | Compounds |
| JP5226513B2 (ja) * | 2005-08-26 | 2013-07-03 | メルク セローノ ソシエテ アノニム | ピラジン誘導体及びその使用 |
| EP1931642A4 (fr) | 2005-09-15 | 2011-06-01 | Orchid Res Lab Ltd | Nouveaux pyrimidine carboxamides |
| US7525866B2 (en) | 2006-04-19 | 2009-04-28 | Freescale Semiconductor, Inc. | Memory circuit |
| FI20065449A0 (fi) | 2006-06-29 | 2006-06-29 | Nokia Corp | Tehonkulutuksen valvontamenetelmä, tehonkulutuksen valvontalaite, tietokoneohjelmatuote, tietokoneohjelman jakeluväline ja kommunikaatioväline |
| TW200840581A (en) | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
| UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
| ITRN20070034A1 (it) | 2007-06-27 | 2008-12-28 | Sica Spa | Macchina e metodo di taglio di un tubo estruso in continuo in spezzoni di minore e predeterminata lunghezza. |
| TWI441601B (zh) | 2007-06-28 | 2014-06-21 | Philip Morris Products Sa | 具有高白堊含量之圖案化包裝紙 |
| CA2697166A1 (fr) | 2007-07-26 | 2009-01-29 | Comentis, Inc. | Composes qui inhibent l'activite de la beta-secretase et procedes d'utilisation de ceux-ci |
| ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
| EP2303890A4 (fr) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | Inhibiteurs de phosphatidylinositol 3 kinase |
| NZ595307A (en) | 2009-03-24 | 2013-11-29 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| KR101818895B1 (ko) | 2009-07-02 | 2018-01-15 | 메르츠 파마 게엠베하 운트 코. 카가아 | 생물학적 활성이 감소된 신경독 |
| WO2011058109A1 (fr) * | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Dérivés de pyrrole et d'imidazole bicycliques condensés en tant qu'inhibiteurs de kinase |
| WO2011119704A1 (fr) | 2010-03-23 | 2011-09-29 | Glaxosmithkline Llc | Antagonistes de trpv4 |
| AU2011255218B2 (en) * | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| EP2394998A1 (fr) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4 |
| WO2012000202A1 (fr) | 2010-07-02 | 2012-01-05 | Tsai Wen-Kai | Dispositif d'envoi de personnel de service et procédé d'envoi de personnel utilisant ledit dispositif |
| JP2013532688A (ja) | 2010-07-26 | 2013-08-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物 |
| EP2598480B1 (fr) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1 |
| EP2699257A4 (fr) | 2011-04-21 | 2014-10-15 | Univ Louisiana State | Vaccins de peptide et conjugué pour infections fongiques |
| EP2518070A1 (fr) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K |
| CN102229416B (zh) | 2011-06-29 | 2013-06-05 | 三一汽车起重机械有限公司 | 一种起重机闭式回转液压系统及起重机 |
| SI2755965T1 (sl) | 2011-09-12 | 2017-12-29 | Merck Patent Gmbh | Novi imidazolni amidi kot modulatorji kinazne aktivnosti |
| WO2014015523A1 (fr) | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Nouveaux composés hétéroaryliques et hétérocycliques et compositions et procédés s'y rapportant |
-
2013
- 2013-10-15 BR BR112015007231A patent/BR112015007231A2/pt not_active IP Right Cessation
- 2013-10-15 AU AU2013333938A patent/AU2013333938A1/en not_active Abandoned
- 2013-10-15 CN CN201380065926.2A patent/CN104854108A/zh active Pending
- 2013-10-15 US US14/435,851 patent/US9388189B2/en not_active Expired - Fee Related
- 2013-10-15 EA EA201500426A patent/EA027277B1/ru not_active IP Right Cessation
- 2013-10-15 AP AP2015008328A patent/AP2015008328A0/xx unknown
- 2013-10-15 JP JP2015537230A patent/JP2015533181A/ja not_active Withdrawn
- 2013-10-15 EP EP13779788.2A patent/EP2909207A1/fr not_active Withdrawn
- 2013-10-15 GE GEAP201313828A patent/GEP201706623B/en unknown
- 2013-10-15 SG SG11201502032VA patent/SG11201502032VA/en unknown
- 2013-10-15 KR KR1020157009063A patent/KR20150068953A/ko not_active Application Discontinuation
- 2013-10-15 MD MDA20150048A patent/MD20150048A2/ro not_active Application Discontinuation
- 2013-10-15 MX MX2015004327A patent/MX2015004327A/es unknown
- 2013-10-15 WO PCT/EP2013/071551 patent/WO2014060432A1/fr active Application Filing
- 2013-10-15 PE PE2015000410A patent/PE20150637A1/es not_active Application Discontinuation
- 2013-10-15 CA CA2883426A patent/CA2883426A1/fr not_active Abandoned
- 2013-10-16 UY UY0001035086A patent/UY35086A/es not_active Application Discontinuation
- 2013-10-16 AR ARP130103757A patent/AR093036A1/es unknown
- 2013-10-16 TW TW102137293A patent/TW201429975A/zh unknown
-
2015
- 2015-02-23 ZA ZA2015/01220A patent/ZA201501220B/en unknown
- 2015-02-26 IL IL237475A patent/IL237475A0/en unknown
- 2015-03-24 TN TNP2015000112A patent/TN2015000112A1/fr unknown
- 2015-03-30 CR CR20150175A patent/CR20150175A/es unknown
- 2015-03-30 DO DO2015000077A patent/DOP2015000077A/es unknown
- 2015-04-13 PH PH12015500813A patent/PH12015500813B1/en unknown
- 2015-04-15 CL CL2015000956A patent/CL2015000956A1/es unknown
- 2015-04-16 NI NI201500054AA patent/NI201500054A/es unknown
- 2015-04-16 GT GT201500094A patent/GT201500094A/es unknown
- 2015-12-01 HK HK15111815.3A patent/HK1211027A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015004327A (es) | 2015-06-10 |
| US20150291595A1 (en) | 2015-10-15 |
| JP2015533181A (ja) | 2015-11-19 |
| MD20150048A2 (ro) | 2015-10-31 |
| CN104854108A (zh) | 2015-08-19 |
| GT201500094A (es) | 2017-08-01 |
| EA201500426A1 (ru) | 2015-10-30 |
| PH12015500813A1 (en) | 2015-06-08 |
| EP2909207A1 (fr) | 2015-08-26 |
| BR112015007231A2 (pt) | 2017-07-04 |
| IL237475A0 (en) | 2015-04-30 |
| DOP2015000077A (es) | 2015-04-30 |
| GEP201706623B (en) | 2017-02-10 |
| AR093036A1 (es) | 2015-05-13 |
| CR20150175A (es) | 2015-05-11 |
| ZA201501220B (en) | 2017-04-26 |
| NI201500054A (es) | 2016-02-01 |
| CA2883426A1 (fr) | 2014-04-24 |
| KR20150068953A (ko) | 2015-06-22 |
| AU2013333938A1 (en) | 2015-04-09 |
| CL2015000956A1 (es) | 2015-06-19 |
| PE20150637A1 (es) | 2015-05-08 |
| HK1211027A1 (en) | 2016-05-13 |
| AP2015008328A0 (en) | 2015-03-31 |
| TW201429975A (zh) | 2014-08-01 |
| WO2014060432A1 (fr) | 2014-04-24 |
| EA027277B1 (ru) | 2017-07-31 |
| TN2015000112A1 (en) | 2016-06-29 |
| PH12015500813B1 (en) | 2015-06-08 |
| UY35086A (es) | 2014-05-30 |
| US9388189B2 (en) | 2016-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284539A (en) | Heterocycloamines as PI3K inhibitors | |
| HRP20181429T1 (hr) | Novi derivati benzimidazola kao inhibitori kinaze | |
| HK1211027A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors pi3k | |
| HK1195552A1 (en) | Pyrrolotriazinone derivatives as pi3k inhibitors pi3k | |
| SG10202003090VA (en) | PI3K δ INHIBITOR | |
| HK1210771A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors |